Keryx Biopharma Announces Commercial Launch Of AURYXIA Tablets In The U.S.

(RTTNews) - Keryx Biopharmaceuticals, Inc. (KERX) said that it has begun shipping AURYXIA tablets to wholesalers in the U.S. Auryxia is approved for the control of serum phosphorus levels in patients with chronic kidney disease or CKD on dialysis.

The company stated that Auryxia is the first and only absorbable-iron-based phosphate binder that is clinically proven to effectively control phosphate levels within the KDOQI guidelines range of 3.5 mg/dL to 5.5 mg/dL. The U.S. Food and Drug Administration or FDA approved Auryxia in September 2014.

"We are extremely proud to bring Auryxia to market in the U.S. Auryxia is a new treatment option for nephrologists that fits squarely into their current treatment protocols," said Ron Bentsur, Chief Executive Officer of Keryx. "We have built a world-class renal commercial team at Keryx and are eager to deliver the first and only absorbable-iron-based phosphate binder to dialysis patients."